Изменения биохимических маркеров у российских пациентов с различными формами рассеянного склероза: КЛИНИЧЕСКАЯ ЛАБОРАТОРНАЯ ДИАГНОСТИКА

Александр Николаевич  Чернов; Екатерина Геннадьевна  Батоцыренова; Ольга Валерьевна  Шамова; Кристина Михайловна  Щепеткова; Вадим Анатольевич  Кашуро

Changes in biochemical markers in Russian patients with various forms of multiple sclerosis

CLINICAL LABORATORY DIAGNOSTICS

Alexander N. Chernov Saint Petersburg State Pediatric Medical University; Institute of Experimental Medicine https://orcid.org/0000-0003-2464-7370
Ekaterina G. Batotsyrenova Saint Petersburg State Pediatric Medical University https://orcid.org/0000-0003-3827-4579
Olga V. Shamova Institute of Experimental Medicine https://orcid.org/0000-0002-5168-2801
Kristina M. Shchepetkova Saint Petersburg State Pediatric Medical University https://orcid.org/0000-0002-8250-4178
Vadim A. Kashuro Saint Petersburg State Pediatric Medical University; Saint Petersburg State University https://orcid.org/0000-0002-7892-0048

Keywords:

multiple sclerosis biomarkers multiplex analysis cytokines growth factors autoimmune disease рассеянный склероз биомаркеры мультиплексный анализ цитокины факторы роста аутоиммунные заболевания

Abstract

Introduction. Clinical symptoms and immunological mechanisms of multiple sclerosis are highly individual, therefore, for the diagnosis and treatment of multiple sclerosis, it is necessary to search for key diagnostic biomarkers. The aim of the study was to evaluate the spectrum of hematological biomarkers in patients with multiple sclerosis for the differential diagnosis of its various forms. Materials and methods. The study included biomaterial (blood serum and plasma) from 102 patients (31 men and 72 women) aged 47.9±5.0 years. The experimental group consisted of 63 patients (21 men and 42 women) aged 46.5±1.2 years with a diagnosis of multiple sclerosis and its various forms: relapsing-remitting, secondary progressive, and primary progressive. The control group consisted of samples from 39 apparently healthy donors (10 men and 29 women) aged 52.4±14.5 years. Protein biomarker concentrations in serum and plasma were analyzed using multiplex immunofluorescence assay using the HCYTOMAG-60K, HADK1MAG-61K, HND3MAG-39K-07, HNDG3MAG-36K, and
HCMBMAG-22K MILLIPLEX MAP reagent panels (Merck, Millipore, USA). Results. In all groups of patients with multiple sclerosis, there was an increase in resistin (relapsing-remitting multiple sclerosis p=0.0007, secondary progressive multiple sclerosis p=0.0401, primary progressive multiple sclerosis p=0.0005) and NSE (secondary progressive multiple sclerosis p=0.0012, relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis p <0.0001), a decrease in MCP-1 (secondary progressive multiple sclerosis p=0.0193, relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis p <0.0001) and eotaxin (relapsing-remitting multiple sclerosis p=0.0172, secondary progressive multiple sclerosis p=0.0364, primary progressive multiple sclerosis p=0.003). In patients with primary progressive multiple sclerosis and relapsing-remitting multiple sclerosis, an increase in IP-10 (p <0.0001 and p=0.0009) and a decrease in PDGF-AB/BB (p=0.0013) were detected. In the secondary progressive multiple sclerosis and primary progressive multiple sclerosis groups, an increase in VCAM-1 was found (p=0.0008 and p=0.0003), while in the primary progressive multiple sclerosis group, a decrease in contactin-1 (p=0.0002) and kallikrein-6 (p=0.0004) levels was also noted. Conclusions. Thus, it was established that biomarker changes in multiple sclerosis patients depend on the disease course.

Author Biographies

Alexander N. Chernov, Saint Petersburg State Pediatric Medical University; Institute of Experimental Medicine

Cand. Sci. (Biol.), Assistant, Dept. of Biological Chemistry, Saint Petersburg State Pediatric Medical University; Senior Researcher, Dept. of General Pathology and Pathological Physiology, Institute of Experimental Medicine

Ekaterina G. Batotsyrenova, Saint Petersburg State Pediatric Medical University

Dr. Sci. (Biol.), Associate Professor, Head, Dept. of General and Medicinal Chemistry named after prof. V.V. Khorunzhy; Professor, Dept. of Biological Chemistry

Olga V. Shamova, Institute of Experimental Medicine

Dr. Sci. (Biol.), Associate Professor, Corresponding Member of the Russian Academy of Sciences, Head, Dept. of General Pathology and Pathological Physiology

Kristina M. Shchepetkova, Saint Petersburg State Pediatric Medical University

Assistant, Dept. of Biological Chemistry

Vadim A. Kashuro, Saint Petersburg State Pediatric Medical University; Saint Petersburg State University

Dr. Sci. (Med.), Associate Professor, Head, Dept. of Biological Chemistry, Saint Petersburg State Pediatric Medical University; Professor, Dept. of Maxillofacial Surgery and Surgical Dentistry, Saint Petersburg State University

References

1. Wallin M.T., Culpepper W.J., Nichols E. et al. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019.18(3):269–285. https://doi.org/10.1016/S1474-4422(18)30443-5.

2. Пажигова З.Б., Карпов С.М., Шевченко П.П., Бурнусус Н.И. Распространенность рассеянного склероза в мире (обзорная статья). Международный журнал экспериментального образования. 2014.(1–2):78–82. Edn: Rtevax.

3. Lassmann H. The contribution of neuropathology to multiple sclerosis research. Eur J Neurol. 2022.29(9): 2869–2877. https://doi.org/10.1111/ene.15360.

4. Singh V., Zheng Y., Ontaneda D. et al. Disability independent of cerebral white matter demyelination in progressive multiple sclerosis. Acta Neuropathol. 2024.148(1):34. https://doi.org/10.1007/s00401-024-02796_w.

5. Fu Q., Schoenhoff F.S., Savage W.J. et al. Multiplex assays for biomarker research and clinical application: translational science coming of age. Proteomics Clin Appl. 2010.4(3):271–284. https://doi.org/10.1002/prca.200900217.

6. van Belle G. Fisher L.D., Heagerty P.J., Lumley T. Biostatistics: a methodology for the helth sciences. L.D. Fisher, G. van Belle, Eds. Canada: Jonh Wiley Interscience. 2004. 896 p.

7. Düzel B., Tamam Y., Çoban A., Tüzün E. Adipokines in multiple sclerosis patients with and without optic neuritis as the first clinical presentation. Immunol Invest. 2019.48(2):190–197. https://doi.org/10.1080/08820139.2018.1528270.

8. Koch M.W., George S., Wall W., Wee Yong V., Metz L.M. Serum Nse level and disability progression in multiple sclerosis. J Neurol Sci. 2015.350(1–2):46–50. https://doi.org/10.1016/j.jns.2015.02.009.

9. Tejera Alhambra M., Casrouge A., de Andrés C., Seyfferth A., Ramos Medina R. et al. Plasma biomarkers discriminate clinical forms of multiple sclerosis. Plos One. 2015.10(6):e0128952. https://doi.org/10.1371/journal.pone.0128952.

10. Adzemovic M.Z., Ockinger J., Zeitelhofer M. et al. Expression of Ccl11 associates with immune response modulation and protection against neuroinflammation in rats. Plos One. 2012.7(7):e39794. https://doi.org/10.1371/journal.pone.0039794.

11. Хальчицкий С.Е., Становая В.В., Янушко М.Г. и др. Нейровоспалительная теория шизофрении. Роль иммуногенетических факторов. Медлайн.ру. 2024.25(17):257–318.

12. Kroksveen A.C., Guldbrandsen A., Vedeler C., Myhr K.M., Opsahl J.A., Berven F.S. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurol Scand Suppl. 2012.(195):90–96. https://doi.org/10.1111/ane.12029.

13. Ubogu E.E., Cossoy M.B., Ransohoff R.M. The expression and function of chemokines involved in Cns inflammation. Trends Pharmacol Sci. 2006.27(1):48–55. https://doi.org/10.1016/j.tips.2005.11.002.

14. Banisor I., Leist T.P., Kalman B. Involvement of beta chemokines in the development of inflammatory demyelination. J Neuroinflammation. 2005.2(1):7. https://doi.org/10.1186/1742-2094-2-7.